0.54Open0.54Pre Close0 Volume66 Open Interest7.50Strike Price0.00Turnover91.49%IV10.77%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.54Extrinsic Value100Contract SizeAmericanOptions Type-0.3849Delta0.1859Gamma12.00Leverage Ratio-0.0127Theta-0.0027Rho-4.62Eff Leverage0.0086Vega
Foghorn Therapeutics Stock Discussion
loading...
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet